Company news
Opthea Limited (ASX:OPT) news
Opthea Limited news releases on 6ix. Latest, Oct 12, 2020: Opthea Launches Proposed US Initial Public Offering
Press releases — page 3
Opthea Launches Proposed US Initial Public Offering
October 12, 2020
Results of Meeting
October 11, 2020
Opthea Files Registration Statement for Proposed US IPO
September 24, 2020
Opthea Full Year Financial Report 2020
August 27, 2020
Opthea Announces Plans for Potential US listing and IPO
August 23, 2020
Opthea Completes Successful FDA and EMA Meetings for Phase 3
August 20, 2020
Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)
July 26, 2020
S&P DJI Announces June 2020 Quarterly Rebalance
June 11, 2020
Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
June 9, 2020
Opthea Completes Patient Dosing in Phase 2a DME Trial
March 29, 2020
Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
January 6, 2020
Opthea Equity Raising Presentation
December 1, 2019
Opthea Presentation for Ophthalmology Innovation Summit
October 10, 2019
Opthea Receives A$14.6m R&D Tax Incentive
September 30, 2019
Opthea Presentation for EURETINA Congress
September 5, 2019
Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
September 3, 2019
Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
August 6, 2019
Opthea European Patent Application to be Granted
July 29, 2019
Opthea Provides Timing Update on OPT-302 Clinical Trials
July 21, 2019
Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
May 14, 2019
S&P DJI Announces March 2019 Quarterly Rebalance
March 7, 2019
Opthea Ph2b Trial Advances With 2nd Positive Safety Review
March 6, 2019
Opthea Granted Japanese Patent Covering OPT-302
January 28, 2019
Opthea Options Exercise Generates Proceeds of A$13.3m
November 28, 2018
Opthea confirms final patient enrolment in Ph2b wAMD trial
November 25, 2018
Opthea Phase 2b wAMD trial fully recruited ahead of schedule
November 13, 2018
Opthea Receives A$12m R&D Tax Incentive
October 30, 2018
Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
October 25, 2018
Opthea Doses First Patients in Australia for Phase 2a in DME
September 16, 2018
Opthea presents Ph1/2a wAMD data at Retina Society Meeting
September 13, 2018
Opthea Receives Positive Safety Review for Ph2b wAMD Trial
September 4, 2018
Opthea Appendix 4E and Annual Report 2018
August 27, 2018
Opthea Doses First Patient in Ph2a Trial for OPT-302 in DME
July 29, 2018
Opthea Meets Primary Safety Objective in DME Phase 1b trial
July 25, 2018
Opthea reaches mid-way in recruitment for Ph2b wAMD trial
July 1, 2018
Opthea Doses wAMD Patients in Europe and Israel
March 26, 2018
Opthea Receives A$2.7m R&D Tax Incentive
January 7, 2018
Opthea Initiates OPT-302 Diabetic Macular Edema Trial
January 2, 2018
Opthea Doses First Patient in OPT-302 wAMD Ph2b trial
December 18, 2017
Opthea Granted Key United States Patent Covering OPT-302
August 30, 2017
Opthea Appendix 4E and Annual Report 2017
August 29, 2017
Opthea Presents Further Positive Data from OPT-302 Ph1/2A
August 14, 2017
Opthea Allowed Key Patent for OPT-302 in United States
July 5, 2017
Opthea Completes A$45 Million Capital Raising
April 27, 2017
Opthea Successfully Completes Institutional Capital Raising
April 4, 2017
Opthea Launches A$45M Financing for Clinical Development
April 2, 2017
Opthea Receives EU Regulatory Feedback for OPT-302 Program
March 19, 2017
Opthea Completes FDA Meeting to Inform OPT-302 Program
March 8, 2017
Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
November 20, 2016
Opthea receives $2.6M R&D tax incentive
October 16, 2016